Cannabis Science, Inc. (CBIS) Issues 2019 Guidance Report

Cannabis Science Issues 2019 Guidance Report; Under SEC Sanctions the Company Goes…

Cannabis Science, Inc. (CBIS) Enters Transition Stage as Trading of the Company’s Shares is Halted

Cannabis Science Enters Transition Stage as Trading of the Company’s Shares is…

Cannabis Science, Inc. (CBIS) Partners With CDN Firm NHS Industries

Cannabis Science Partners With CDN Firm NHS Industries to Launch the CBIS…

Mr. Raymond C. Dabney Prepares Cannabis Science, Inc. (CBIS) for the Next Level

Mr. Raymond C. Dabney Prepares Cannabis Science for the Next Level With…

Cannabis Science, Inc. (CBIS) Set to Participate in the Premier Event Focused on High-Impact Global Collaborations

Cannabis Science Set to Participate in the Premier Event Focused on High-Impact…

Cannabis Science, Inc. (CBIS) Releases Clinical Drug-Development Pipeline

Cannabis Science Releases Clinical Drug-Development Pipeline as it Transitions Into Clinical Trials;…

Cannabis Science, Inc. (CBIS) Negotiates Licensing and Marketing Deals in Canada and the USA to Develop and Sell CBN Products

Independent Valuation of U.S. Patent Number 9,763,991 for Cannabinol (CBN) Initiated as…

Cannabis Science, Inc. (CBIS) Receives Tremendous Response for CEO’s Personal Shareholder Loyalty Gift

Cannabis Science Receives Tremendous Response for CEO’s Personal Shareholder Loyalty Gift; Planning…

$CBIS Form 10-Q/A

Form 10-Q/A for CANNABIS SCIENCE, INC. 24-Nov-2015 Quarterly Report ITEM 2. MANAGEMENT’S…

$CBIS Highlights Additional Attendees at the Washington DC, African Union

Cannabis Science Highlights Additional Attendees at the Washington DC, African Union, CFA…